Gaze Shift to Screen Edge Boosts Colorectal Adenoma Detection: Multicenter Randomized Controlled Trial (EYE-SIGHT Trial).

Clin Gastroenterol HepatolJan 27, 2026 (epub)
Clinical ResearchGastroenterology

Fumiaki Ishibashi, Satoshi Ono, Kosuke Okusa et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial tested whether real-time eye-tracking prompts to direct endoscopists’ gaze toward the screen periphery improved colorectal polyp detection. Across four institutions, 400 adults aged 40 to 90 years were enrolled; 198 were assigned to gaze guidance and 199 to control. Adenomas per colonoscopy were higher with guidance (1.34 vs 0.95; P = .046). Adenoma and polyp detection rates also improved, while observation time did not differ significantly. The findings suggest that peripheral-gaze prompts can increase detection without prolonging the procedure.

Key findings

  • Adenomas per colonoscopy were 1.34 with gaze guidance versus 0.95 in controls (P = .046).
  • Adenoma detection rate was 53.3% versus 39.2% (P = .007), and polyp detection rate was 66.5% versus 47.2% (P < .001).
  • Peripheral gaze rate increased from 25.9% to 33.7% (P < .001); observation time was 8.4 versus 8.0 minutes (P = .094).

Why it matters

Adenoma detection is central to colonoscopy’s role in colorectal cancer prevention. This trial indicates that a visual-attention strategy, delivered through real-time feedback, may improve adenoma and polyp detection without a significant increase in observation time. It provides evidence that endoscopist gaze behavior is a potentially modifiable factor in detection performance.

What to keep in mind

The abstract does not report follow-up or outcomes beyond detection and observation time; the trial was conducted at four institutions.

Source

Published in Clin Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.